Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Researchers Say FDA Is Slowing Artificial Pancreas Efforts

This article was originally published in The Gray Sheet

Executive Summary

Developers of "artificial pancreas" devices for treating type 1 diabetes may gain insight from new FDA draft guidance on clinical trial design, but patients and advocates say the agency is standing in the way of greater advances in the space.

You may also be interested in...



Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”

Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.

News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements

FDA approves Medtronic’s MiniMed 530G system, making it the first system in the U.S. that can automatically suspend insulin delivery to people with diabetes. CMS removes bariatric surgery facility certification requirements. More news.

Regulatory News In Brief

FDA issues final guidance on IDE and PMA requirements for artificial pancreas devices. CDRH plans Office of Compliance reorganization. More regulatory news.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel